Mr. Tomás Dagá Gelabert has served as director of Grifols, S.A. since April 2000 and also as vice secretary of the board since May 2016. He is the managing partner and founder of the law firm Osborne Clarke in Spain. Prior to joining Osborne Clarke, he worked in the corporate and tax department of Peat Marwick Mitchell & Co. in Barcelona. He is currently a member of the Board of Directors of Kiro Robotics S.L., Biomat USA, Inc., Talecris Plasma Resources, Inc., Grifols Diagnostic Solutions Inc. and Grifols Worldwide Operations Limited. He is also a trustee and the Secretary of the private foundation Víctor Grífols i Lucas, a trustee of the Probitas Fundación Privada foundation and the Secretary non-board member of the Board of Directors of Progenika Biopharma, S.A. and Araclon Biotech, S.L. Mr Dagá earned his degree in Law from the University of Barcelona (Universidad de Barcelona). Relation with significant shareholders: Tomás Dagá Gelabert is a shareholder of Scranton Enterprise, B.V. (a non-controlling shareholder, pursuant of the Spanish Securities Market Act). 

 Clinical Sciences